The effects of endocrine therapy on sexual function among breast cancer survivors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260527001

Enrollment

147

Registered

2026-05-27

Start date

2025-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Aromatase inhibitor (AIs)

Interventions

Breast cancer survivors currently receiving aromatase inhibitor therapy (anastrozole, letrozole, or exemestane),Breast cancer survivors currently receiving tamoxifen therapy

Screening,Screening

Aromatase Inhibitor group, Tamoxifen group

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Women aged 18 to 65 years with histologically confirmed breast cancer 2.Who are currently receiving endocrine therapy (aromatase inhibitor or tamoxifen) 3.sexually active at least 1 episode past 4 weeks

Exclusion criteria

Exclusion criteria: 1.Other malignancies 2.Severe psychiatric illness, use of SSRIs/antidepressants/antipsychotics, comorbidities affecting sexual response (diabetes, cardiovascular disease, chronic kidney or liver disease). 3.Inability to complete questionnaire

Design outcomes

Primary

Measure	Time frame
Sexual Function 12 month Questionnaire	—

Secondary

Measure	Time frame
To identify associated factors 12 months questionnaires	—

Countries

Thailand

Contacts

Public ContactBenjamaporn Sereenonchai

Chulalongkorn university

md.benjamaporn@gmail.com0902690999

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026